Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN003 vs Trastuzumab/Pertuzumab/Docetaxel in First-Line HER2+ Advanced Breast Cancer
NCT07545044Phase 2Not yet recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of anbenitamab repodatecan in breast cancer, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Planned start May 2026; status: not yet recruiting.
02
Drugs
anbenitamab repodatecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07545044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07545044.